Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05897905
Other study ID # 23CX8211
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date July 24, 2023
Est. completion date August 31, 2024

Study information

Verified date September 2023
Source Imperial College Healthcare NHS Trust
Contact Jennifer Crow
Phone 07795826663
Email jcrow@ic.ac.uk
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The goal of this feasibility study is to ascertain if this follow-up programme of care can feasibly be implemented within a healthcare system with people after minor stroke. The main feasibility questions are: i) To establish recruitment uptake ii) To establish treatment adherence iii) To determine participant retention. Participants will be randomly allocated to the intervention and control group. Those in the intervention group will receive a follow-up telephone call at two weeks after discharge and a second follow-up appointment at six weeks after discharge. Outcome measures will be taken at twelve weeks after discharge.


Recruitment information / eligibility

Status Recruiting
Enrollment 60
Est. completion date August 31, 2024
Est. primary completion date May 31, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Adult =18 - Clinical or radiological diagnosis of minor stroke from a stroke consultant. - Admitted to HASU or seen in rapid assessment/TIA clinic. - Pre-admission mRS of 0-3 with no formal package of care prior to stroke. - Discharge mRS of 0-3. - No onward referral to community therapy team or for package of care. - Has capacity to consent. Exclusion Criteria: - Any serious co-morbidities that would impact a person's ability to participate in the follow-up appointments and outcome measurement. - Insufficient English to engage in intervention and outcome measures and no family or friends to support with this. - Not resident in England. - Pregnant women.

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Personalised, holistic follow-up appointments underpinned by self determination theory
Appointment 1 (two weeks after discharge): Address participants knowledge gaps as regards their stroke, medication and secondary prevention. Detailed biopsychosocial review. Understand participant priorities and jointly set goals. Agreeing onward referrals if needed. Written summary sent to GP with copy to participant. Appointment 2 (six weeks): Review priorities identified in post stroke review checklist. Review goals and plans from first appointment. Address any new or persistent information gaps. Review hidden impairments that may be impacting on return to work, activities of daily living, relationships or general well-being. Agreeing onward referrals and action plan. Written summary and plan sent to GP.

Locations

Country Name City State
United Kingdom Imperial College Healthcare NHS Trust London

Sponsors (1)

Lead Sponsor Collaborator
Imperial College Healthcare NHS Trust

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Other Qualitative interviews Semi-structured 13 weeks
Primary Recruitment rate Proportion of participants randomised relative to the total number meeting the inclusion criteria. Baseline
Primary Treatment completion rate Proportion of participants who attend both follow-up appointments 6 weeks post randomisation
Primary Retention rate Proportion of participants that complete the follow-up questionnaires 12 weeks post randomisation
Secondary PROMIS10 Patient reported outcome measures information system 2 weeks and 12 weeks
Secondary Health Care Climate Questionnaire Short Form Patient reported outcome measure Baseline and 12 weeks
Secondary MOCA Cognitive assessment Baseline and 12 weeks
Secondary PHQ9 Mood score 12 weeks
Secondary GAD7 Anxiety score 12 weeks
See also
  Status Clinical Trial Phase
Recruiting NCT05378035 - DOAC in Chinese Patients With Atrial Fibrillation
Completed NCT03574038 - Transcranial Direct Current Stimulation as a Neuroprotection in Acute Stroke N/A
Completed NCT03679637 - Tablet-based Aphasia Therapy in the Acute Phase After Stroke N/A
Completed NCT03633422 - Evaluation of Stroke Patient Screening
Completed NCT04088578 - VNS-supplemented Motor Retraining After Stroke N/A
Not yet recruiting NCT05534360 - Tenecteplase Treatment in Ischemic Stroke Registry
Withdrawn NCT04991038 - Clinical Investigation to Compare Safety and Efficacy of DAISE and Stent Retrievers for Thrombectomy In Acute Ischemic Stroke Patients N/A
Not yet recruiting NCT04105322 - Effects of Kinesio Taping on Balance and Functional Performance in Stroke Patients N/A
Withdrawn NCT05786170 - ERILs Und SNILs Unter SOC N/A
Recruiting NCT03132558 - Contrast Induced Acute Kidney in Patients With Acute Stroke N/A
Completed NCT02893631 - Assessment of Hemostasis Disorders in rtPA-treated Patients Requiring Endovascular Treatment for Ischemic Stroke
Active, not recruiting NCT02274727 - Biomarker Signature of Stroke Aetiology Study: The BIOSIGNAL-Study
Completed NCT02225730 - Imaging Collaterals in Acute Stroke (iCAS)
Terminated NCT01705353 - The Role of HMGB-1 in Chronic Stroke N/A
Active, not recruiting NCT01581502 - SAMURAI-NVAF Study: Anticoagulant Therapy for Japanese Stroke Patients With Nonvalvular Atrial Fibrillation (NVAF) N/A
Completed NCT01182818 - Fabry and Stroke Epidemiological Protocol (FASEP): Risk Factors In Ischemic Stroke Patients With Fabry Disease N/A
Completed NCT00761982 - Autologous Bone Marrow Stem Cells in Middle Cerebral Artery Acute Stroke Treatment. Phase 1/Phase 2
Completed NCT00535197 - Autologous Bone Marrow Stem Cells in Ischemic Stroke. Phase 1/Phase 2
Terminated NCT00132509 - FRALYSE Trial: Comparison of the Classical Rt-PA Procedure With a Longer Procedure in Acute Ischemic Stroke Phase 2
Recruiting NCT05760326 - Diagnostic and Prognostic Role of Clot Analysis in Stroke Patients